Stockreport

Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences' DecisionDx®-Melanoma Test, Contributing to Personalized Manag...

Castle Biosciences, Inc. - Common stock  (CSTL) 
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm Check Earnings Report
PDF stratification provided by DecisionDx-Melanoma and its potential to significantly improve care for patients with cutaneous melanoma (CM) FRIENDSWOOD, Texas, December 1 [Read more]